Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 173 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inhibitory Control Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

NCT03066115
View directory record Official record
Conditions
Hypoxia, Hypercapnia
Interventions
L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 3, 2026, 1:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

NCT03926117
View directory record Official record
Conditions
Chronic Kidney Diseases, Inflammation
Interventions
Ziltivekimab
Biological
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
49
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04211389
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
ARQ-151 0.3% cream, ARQ-151 vehicle cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Sep 3, 2026, 1:10 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

NCT05665595
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab/Vibostolimab, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 1:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Bases of Multiple Forms of Self-regulatory Control in Bulimia Nervosa

NCT02997475
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Not applicable Interventional

Training Response Inhibition to Obesogenic Foods

NCT04659837
View directory record Official record
Conditions
Inhibitory Control Training, Gameifaction
Interventions
No-Added-Sugar Diet
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 3, 2026, 1:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

NCT04773600
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream, Vehicle cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
44
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 3, 2026, 1:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Breaking Sitting with High-intensity Interval Training for Brain Health

NCT06243016
View directory record Official record
Conditions
Aging
Interventions
High-Intensity Interval Training (HIIT) Breaks to Sitting, Light-Intensity Interval Training (LIIT) Breaks to Sitting
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
40 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 3, 2026, 1:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Dynamics and Connectivity in Response Inhibition and Traumatic Brain Injury

NCT01194661
View directory record Official record
Conditions
Traumatic Brain Injury, Stroke, Headache, PTSD
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 40 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 3, 2026, 1:10 AM EDT
Recruiting Phase 2 Interventional

Ivosidenib as Post-HSCT Maintenance for AML

NCT06707493
View directory record Official record
Conditions
IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ivosidenib, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 2 Interventional

Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR

NCT00001698
View directory record Official record
Conditions
Leukoplakia, Periodontal Disease
Interventions
Ketorolac Rinse
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

NCT00518765
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Aliskiren plus placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Utility of Nexium in Chronic Cough and Reflux Disease

NCT00287339
View directory record Official record
Conditions
Cough, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Sep 3, 2026, 1:10 AM EDT
Terminated Phase 3 Interventional

A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack

NCT00112281
View directory record Official record
Conditions
Shock, Cardiogenic
Interventions
Tilarginine Acetate Injection intravenous infusion
Drug
Lead sponsor
Arginox Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
83
States / cities
Mobile, Alabama • Fort Smith, Arizona • Mesa, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2006 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Inhibitory Control Smartphone App

NCT04243759
View directory record Official record
Conditions
Drinking, Alcohol, Drinking Behavior
Interventions
Control App Version, Standard App Version, Experimental, Feedback App Version
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 3, 2026, 1:10 AM EDT
Active, not recruiting Phase 2 Interventional

Centrally Acting ACE Inhibition in SLE

NCT04486118
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Lisinopril Pills, Benazepril Pill
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Great Neck, New York • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 3, 2026, 1:10 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT05019521
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Danicopan, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
49
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers

NCT03312777
View directory record Official record
Conditions
Pain
Interventions
Omnitram, Tramadol, Placebo
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 3, 2026, 1:10 AM EDT
Not yet recruiting Early Phase 1 Interventional

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA

NCT06081153
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 3, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

NCT02561000
View directory record Official record
Conditions
Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
Interventions
PZ-128, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 3, 2026, 1:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BID WM Digital Intervention in Aging

NCT06918704
View directory record Official record
Conditions
Working Memory, Inhibitory Control, Mild Cognitive Impairment (MCI), Aging
Interventions
Coherence, Worder
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 1:10 AM EDT